High-grade Pelvic Serous Carcinoma Within the Fallopian Tube Lumen: Real or Artifact?

2019 ◽  
Vol 39 (5) ◽  
pp. 460-467
Author(s):  
Jeffrey D. Seidman ◽  
Jayashree Krishnan
Keyword(s):  
Fallopian Tube ◽  
Serous Carcinoma ◽  
High Grade ◽  
Tube Lumen ◽  
Pelvic Serous Carcinoma

scholarly journals Loss of tubal ciliated cells as a risk for “ovarian” or pelvic serous carcinoma

2020 ◽  
Author(s):  
Yue Wang ◽  
Wanrun Lin ◽  
Yiying Wang ◽  
Yan Wang ◽  
Setsuko Chambers ◽  
...  
Keyword(s):  
High Risk ◽  
Fallopian Tube ◽  
Low Risk ◽  
Serous Carcinoma ◽  
Secretory Cells ◽  
High Grade ◽  
Ciliated Cells ◽  
Anatomic Site ◽  
Pelvic Serous Carcinoma

Abstract Background Recent advances suggest the fallopian tube as the main anatomic site for high-grade ovarian or pelvic serous carcinoma (O/PSC). Human fallopian tube is mainly lined by two cell types, secretory and ciliated cells. Large number of studies on the biologic role of tubal secretory cells in O/PSC have been performed in the last decade. However, the role of tubal ciliated cells in relation to the development of O/PSC has rarely been explored. The purpose of this study was to determine if change of the tubal ciliated cells shows difference in age and location and to examine their association with serous neoplasia. Methods Three groups (low-risk or benign control, high-risk, and O/PSC) of patients were age matched. The age data was stratified by 10-year intervals ranging from age 20 to older than 80. Ciliated cells from both tubal fimbria and ampulla segments were counted by microscopy and by tubulin immunohistochemical staining. The data was analyzed by standard contingency table, Poisson distribution methods, nonparametric Mann–Whitney U-tests and Spearman correlation analysis after age justification. Results The study revealed that the absolute number of tubal ciliated cells decreased significantly with age within each group. A reduction in ciliated cells within the fallopian tube remained a significant risk factor for serous neoplasia after age adjustment. A dramatic decrease of tubal ciliated cells in both tubal segments was identified in patients with high-risk and with O/PSC compared to those in the low-risk (benign control) group (p < 0.001). Further, within the fimbria segment, a reduced number of tubal ciliated cells was more prevalent in the high-risk group when compared to those in O/PSC group. Conclusion Our findings suggest that reduced number of ciliated cells within the fallopian tube represents a hallmark of early serous carcinogenesis. Findings also support a relationship between loss of tubal ciliated cells and aging, the presence of high-risk factors, and co-existing ovarian or pelvic high-grade serous cancers. This represents an early study identifying the role of tubal ciliated cells in the process of high-grade O/PSC development.

The Fallopian Tube: Primary Site of Most Pelvic High-grade Serous Carcinomas

2009 ◽  
Vol 19 (1) ◽  
pp. 58-64 ◽  
Author(s):  
Shannon Salvador ◽  
Blake Gilks ◽  
Martin Köbel ◽  
David Huntsman ◽  
Barry Rosen ◽  
...  
Keyword(s):  
Oral Contraceptive ◽  
Fallopian Tube ◽  
English Language ◽  
Contraceptive Use ◽  
Early Stage ◽  
Tubal Ligation ◽  
Serous Carcinoma ◽  
Screening Methods ◽  
High Grade ◽  
Pelvic Serous Carcinoma

Epithelial ovarian cancer is the most common cause of mortality from gynecologic malignancy, and most of epithelial cancers are of serous type. The site of origin of pelvic high-grade serous carcinoma has been the subject of debate for 60 years. This paper reviews the evidence that pelvic serous carcinoma originates from the fallopian tube mucosa and puts forward a theory that inflammation in the tube, caused by menstrual cytokines or infection, is critical to the genesis of these tumors. Other risk factors for pelvic serous carcinoma will be reviewed, including oral contraceptive use, parity, infertility, and tubal ligation.Studies were identified for this review by searching the English language literature in the MEDLINE database between the years 1995 and 2007 using the following keywords: fallopian tube neoplasia, ovarian serous adenocarcinoma, pregnancy, oral contraceptive, infertility, pelvic inflammatory disease, cytokines, menstruation, and tubal ligation, followed by an extensive review of bibliographies from articles found through the search.The clinical implications of this theory are discussed, and a change in surgical practice is recommended, with salpingectomy at the time of simple hysterectomy. This theory also has implications for the development of new methods of screening for pelvic serous carcinomas, as there are no screening methods that are currently available to find this form of cancer in an early stage. Inflammatory markers could be detected in the vagina from the fallopian tube indicating possible chronic inflammation and a risk factor for mutagenesis leading to serous carcinoma.

scholarly journals Culprit or Bystander? The Role of the Fallopian Tube in “Ovarian” High-Grade Serous Carcinoma

2016 ◽  
Vol 6 (12) ◽  
pp. 1309-1311 ◽  
Author(s):  
Elizabeth M. Swisher ◽  
Rochelle L. Garcia ◽  
Mark R. Kilgore ◽  
Barbara M. Norquist
Keyword(s):  
Fallopian Tube ◽  
Serous Carcinoma ◽  
High Grade

High-grade serous carcinoma of Fallopian tube first presenting as axillary lymphadenopathy: a case report

The Breast ◽  
2019 ◽  
Vol 44 ◽  
pp. S65
Author(s):  
T. Kulkovská ◽  
D. Vlčáková ◽  
P. Slávik ◽  
Z. Laučeková ◽  
T. Bielik ◽  
...  
Keyword(s):  
Case Report ◽  
Fallopian Tube ◽  
Serous Carcinoma ◽  
High Grade ◽  
Axillary Lymphadenopathy

scholarly journals Solitary CNS Metastasis on Initial Presentation of High Grade Serous Carcinoma of the Fallopian Tube

2018 ◽  
Vol 2018 ◽  
pp. 1-4 ◽  
Author(s):  
Felicity Harl ◽  
Cassandra Niemi ◽  
Lori Mankowski Gettle ◽  
Paul Weisman ◽  
Stephen Rose
Keyword(s):  
Fallopian Tube ◽  
Brain Lesion ◽  
Primary Site ◽  
Initial Presentation ◽  
Serous Carcinoma ◽  
High Grade ◽  
Metastatic Adenocarcinoma ◽  
Cns Metastasis ◽  
Small Primary ◽  
History Of

A 68-year-old woman presented with a three-week history of confusion and anomic aphasia. Imaging of her head demonstrated a single large left frontal mass. Pathology revealed metastatic adenocarcinoma of Müllerian origin. Subsequent surgery revealed a small primary site in a fallopian tube, high left para-aortic lymphadenopathy, and no disseminated intraperitoneal disease. This case was remarkable in that CNS metastasis was her presenting symptom and was restricted to a solitary brain lesion, and other disease sites were limited to retroperitoneal lymphadenopathy and a small fallopian tube primary.

Validation of Revised FIGO Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum Based on a Single Histological Type

2016 ◽  
Vol 26 (6) ◽  
pp. 1012-1019 ◽  
Author(s):  
Tayfun Toptas ◽  
Elif Pestereli ◽  
Onur Erol ◽  
Selen Bozkurt ◽  
Gulgun Erdogan ◽  
...  
Keyword(s):  
Fallopian Tube ◽  
Stage Iv ◽  
Hazard Ratio ◽  
Stage Iii ◽  
Serous Carcinoma ◽  
Study Cohort ◽  
High Grade ◽  
Subgroup Analyses ◽  
Clinical Records ◽  
Staging Classification

ObjectiveThis study aimed to evaluate the prognostic significance of revised International Federation of Gynecology and Obstetrics (FIGO2013) staging classification for cancer of the ovary, fallopian tube, and peritoneum in patients exhibiting high-grade serous histology.MethodsClinical records of patients with high-grade serous carcinoma who underwent primary surgery between 2007 and 2012 were reviewed retrospectively. Patients were reclassified according to the FIGO2013 criteria. Progression-free survival (PFS) and overall survival (OS) were calculated for each stage using Kaplan-Meier estimates and compared with the log-rank test.ResultsIn total, 125 patients were included in the analysis. The distribution of the study cohort according to the revised classification was as follows; stage I, 6 patients; stage II, 9 patients; stage III, 85 patients; and stage IV, 25 patients. Median follow-up time was 36 months (95% confidence interval [CI], 3–110). The median PFS and OS were 14 months (95% CI, 12.4–15.6) and 60 months (95% CI, 47.0–72.9), respectively. Both PFS and OS were significantly different among stages I, II, III, and IV (P < 0.01). Subgroup analyses for stage III disease also revealed significant differences in survival. The median PFS for stages IIIA1, IIIB, and IIIC was 56, 46, and 16 months, respectively (P < 0.01), and the median OS was 104, 95, and 60 months, respectively (P = 0.03). The outcomes of patients with stage IV disease differed slightly but nonsignificantly according to new substages. The median PFS for stages IVA and IVB was 12 and 6 months, respectively (hazard ratio, 1.16; 95% CI, 0.48–2.79; P = 0.72), and the median OS was 41 and 24 months, respectively (hazard ratio, 1.62; 95% CI, 0.58–4.55; P = 0.35). The study sample was insufficient in size for subgroup analyses in stages I and II.ConclusionsThe revised FIGO2013 staging system is highly prognostic for discriminating outcomes of patients with high-grade serous carcinoma across stages I to IV, in subgroups of stage III, but not in subgroups of stage IV.

Sign in / Sign up

Export Citation Format

Share Document